A pilot study of zafirlukast as an anti-inflammatory agent in the treatment of adults with cystic fibrosis (Q45088961)

9 December 2017

title

A pilot study of zafirlukast as an anti-inflammatory agent in the treatment of adults with cystic fibrosis (English)

1 reference

9 December 2017

0 references

1 reference

S P Conway

1 reference

9 December 2017

C Etherington

series ordinal

1 reference

9 December 2017

D G Peckham

series ordinal

1 reference

9 December 2017

A Whitehead

series ordinal

1 reference

9 December 2017

language of work or name

1 reference

1 March 2003

1 reference

Journal of Cystic Fibrosis

9 December 2017

published in

1 reference

9 December 2017

1 reference

9 December 2017

1 reference

9 December 2017

page(s)

25-28

1 reference

Leukotrienes as a target in asthma therapy

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900142-X

7 January 2021

Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900142-X

7 January 2021

Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900142-X

7 January 2021

Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900142-X

7 January 2021

Leukotrienes in the sputum and urine of cystic fibrosis children

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900142-X

7 January 2021

Sputum cysteinyl‐leukotriene levels correlate with the severity of pulmonary disease in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900142-X

7 January 2021

Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900142-X

7 January 2021

Montelukast sodium in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900142-X

7 January 2021

Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900142-X

7 January 2021

Validation of a vertical visual analogue scale as a measure of clinical dyspnea

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900142-X

7 January 2021

A new prognostic score and clinical evaluation system for cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900142-X

7 January 2021

The two-period cross-over clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900142-X

7 January 2021

Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900142-X

7 January 2021

Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2802%2900142-X

7 January 2021

10.1016/S1569-1993(02)00142-X

Identifiers

DOI

1 reference

9 December 2017

1 reference